| 000 | 01733cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030950.0 | ||
| 008 | 140409s2013 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.07.M.Sc.2013.Lu.T | ||
| 100 | 0 | _aLucie Gamal Fawzi | |
| 245 | 1 | 0 |
_aTET2 mutation in myeloid neoplasms / _cLucie Gamal Fawzi ; Supervised Aisha Mostafa Abdelraman , Hoda Mohamed Abdelghany , Reham Ahmed Rashed |
| 246 | 1 | 5 | _aالطفرة الكروموزمية فى الورم الميلودى:TET2 |
| 260 |
_aCairo : _bLucie Gamal Fawzi , _c2013 |
||
| 300 |
_a127 P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
| 520 | _aIn acute myloid leukemia (AML), both cytogenetic and molecular abnrmalities are strongly assosiated with prognosis. In particular, in cytogenetically normal AML. Families of myeloproliferaive neoplasms (MPNs) are characterized by a clinical and genetic heterogenceity. First, within MPN families, distinct clinical entities are observed, the 3 main ones being polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PME) | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAcute lymphoblastic leukemia | |
| 653 | 4 | _aAlpha naphthly acetate | |
| 653 | 4 | _aPrimary myelofibrosis (PME) | |
| 700 | 0 |
_aAisha Mostafa Abdelraman , _eSupervisor |
|
| 700 | 0 |
_aHoda Mohamed Abdelghany , _eSupervisor |
|
| 700 | 0 |
_aReham Ahmed Rashed , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAml _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c45666 _d45666 |
||